YENOM NOTICIAS
Noticias financieras organizadas para conectar titulares, símbolos, fuente, fecha y sentimiento con tu análisis y operativa.
Si escribes ticker, YENOM prioriza ese instrumento. Si lo dejas vacío puedes explorar el feed general o por tema.
Company Logo Newly released 9th edition sizes the market at US$8.14 billion in 2025, with ctDNA leading and analysis of AI's impact. Profiles 117 companies including Guardant Health, Natera and Exact Sciences. Dublin, Oct. 08, 2026 (GLOBE…
3 Market-Beating Stocks with Competitive Advantages Stocks that outperform the market usually share key traits such as rising sales, expanding margins, and increasing returns on capital. The select few that can do all three for many years…
First patients enrolled in multi-center trial evaluating MRD-guided escalation for patients with advanced melanoma AUSTIN, Texas, October 07, 2026--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precisio…
1 Unpopular Stock That Deserves Some Love and 2 Facing Challenges When Wall Street turns bearish on a stock, it's worth paying attention. These calls stand out because analysts rarely issue grim ratings on companies for fear their firms wi…
Four oral presentations spanning gastrointestinal and gynecologic cancers demonstrated Signatera's role in informing personalized care management, including radiotherapy treatments AUSTIN, Texas, October 06, 2026--(BUSINESS WIRE)--Natera,…
2 Growth Stocks to Stash and 1 That Underwhelm Growth boosts valuation multiples, but it doesn't always last forever. Companies that cannot maintain it are often penalized with large declines in market value, a lesson ingrained in investor…
Trial will use Natera's ultrasensitive MRD test, Signatera Genome with Phased and Structural Variants, paired with giredestrant monotherapy, Genentech's investigational oral SERD, aiming to spare patients unnecessary CDK4/6 inhibitor expos…
Global bond markets have just steadied after a sharp sell off that pushed US borrowing costs to levels last seen in 2002, which keeps reliable cash generation and robust finances firmly in focus. That backdrop puts financially solid health…
1 Unprofitable Stock to Target This Week and 2 We Question Unprofitable companies can burn through cash quickly, leaving investors exposed if they fail to turn things around. Without a clear path to profitability, these businesses risk run…
During these busy times, it pays to stay on top of the latest profit opportunities. And today's blog post should be a great place to start. After taking a close look at the latest data on institutional buying pressure and each company's fu…
Check out the companies making headlines yesterday: AutoZone (NYSE:AZO): Auto parts and accessories retailer AutoZone (NYSE:AZO) rose by 6.1% on Tuesday after the company reported fourth-quarter earnings per share above Wall Street expecta…
Natera NTRA recently announced that its Signatera test received regulatory approval from Japan's Pharmaceuticals and Medical Devices Agency (PMDA) as a companion diagnostic (CDx) for use in muscle-invasive bladder cancer (MIBC). The approv…
Why Is Natera (NTRA) Stock Soaring Today What Happened? Shares of genetic testing company Natera (NASDAQ:NTRA) jumped 5.2% in the afternoon session after the company announced that Japan's Pharmaceuticals and Medical Devices Agency granted…
Company Logo The global NICU genetic testing market is forecast to grow from USD 1.74 billion in 2026 to USD 4.80 billion by 2036, at a 10.67% CAGR. Growth is driven by rising neonatal genetic disorders, rapid whole genome and exome sequen…
Second PMDA approval for Signatera in three months and first PMDA-approved CDx in MRD-guided care; commercial launch expected in 1H'27, pending final reimbursement and pricing AUSTIN, Texas, September 22, 2026--(BUSINESS WIRE)--Natera, Inc…
Natera and its collaborators recently presented four abstracts at the IASLC 2026 World Conference on Lung Cancer, including the largest molecular residual disease dataset to date in resected stage 1–3 non-small cell lung cancer, showing th…
Natera's updated analyst models now point to a higher Fair Value price target of US$344.33, up from US$282.14, which is roughly a 22% change in the modeled outcome. Analysts are tying this shift to how Natera is executing in molecular resi…
Steven Leonard Chapman, CEO and President of Natera (NASDAQ:NTRA), sold 1,698 shares of common stock on Sept. 1, 2026, according to a recent SEC Form 4 filing. Transaction summary Metric Value Transaction value $545,000 Shares sold 1,698 P…
Data on >1,100 patients presented at the World Conference on Lung Cancer shows Signatera MRD status strongly predicted recurrence-free and overall survival in resected non-small cell lung cancer, with findings consistent across primary sur…
A concept photo of a DNA structure by robsonphoto via Adobe Stock Natera (NTRA) demonstrates strong technical momentum, with shares hitting a new all-time high. Shares are up more than 105% over the past year. Valuation concerns persist, a…
Stanley Druckenmiller has quite a long and distinguished career as an investor. Much of this has to do with high-risk bets that have paid off enormously, such as when he and his boss, George Soros at Quantum Fund, shorted the U.K. pound fo…
With the stock market on shaky ground, investors should be adjusting their portfolio management and taking some profits. For about a half-dozen components of Investor's Business Daily's IBD 50 list, the decision on when to sell stocks is a…
3 Reasons Investors Love Natera (NTRA) What a time it's been for Natera. In the past six months alone, the company's stock price has increased by a massive 59.9%, reaching $328.13 per share. This was partly due to its solid quarterly resul…
Natera, Inc. (NASDAQ:NTRA) is expanding across oncology, women's health and organ transplantation, but Jim Cramer says the stock's valuation has become difficult to justify after a sharp rally. During the September 3 episode of Mad Money,…
One of the best investors riding the artificial intelligence (AI) revolution is Stanley Druckenmiller at the Duquesne Family Office. Druckenmiller is a famous trend follower and was one of the early traders to buy into Nvidia (NASDAQ: NVDA…
[Health Care Medical Stock Market Industry Sector Wall Street Buildings 3d Illustration] iQoncept/iStock via Getty Images With the second-quarter earnings season now largely behind us, investors are turning their attention to how healthcar…
Launched on January 26, 2004, the Vanguard Morningstar Small-Cap Growth ETF (VBK) is a passively managed exchange traded fund designed to provide a broad exposure to the Small Cap Growth segment of the US equity market. The fund is sponsor…
Signatera demonstrates 100% positive predictive value for treatment response assessment, detects recurrence months earlier than imaging, and supports precise, individualized lymphoma management through serial ctDNA monitoring AUSTIN, Texas…
3 Momentum Stocks to Own for Decades The stocks featured in this article are seeing some big returns. Over the past month, they've outpaced the market due to some combination of positive news, upbeat results, or supportive macro developmen…
Vanguard Morningstar Mega Cap Growth ETF (NYSEMKT:MGK) and Vanguard Morningstar Small-Cap Growth ETF (NYSEMKT:VBK) offer low-cost access to growth-oriented stocks but target opposite ends of the market-capitalization spectrum. Vanguard Mor…
Some investors throw money at lots of stocks and hope that enough become winners to offset the inevitable losers. That isn't the approach Stanley Druckenmiller takes. The billionaire only invests in high-conviction stocks after a thorough…
Natera NTRA recently announced a collaboration with Angiex, Inc. to assess treatment response to AGX101, an investigational nuclear-delivered antibody-drug conjugate (ND-ADC), using its Signatera test. The Phase 1 trial is evaluating AGX10…
The partnership combines Natera's leadership in breast cancer research and personalized molecular residual disease (MRD) testing with Susan G. Komen's global advocacy and patient support network AUSTIN, Texas, August 28, 2026--(BUSINESS WI…
3 Healthcare Stocks with Promising Prospects Personal health and wellness is one of the many secular tailwinds for healthcare companies. Players catalyzing medical advancements have benefited from elevated demand, and their momentum is onl…
Natera recently announced a collaboration with Kupando Therapeutics to supply its Latitude tissue-free MRD assay for a Phase 1 immunotherapy trial in multiple skin cancers, expanding the use of its technology in oncology research. At the s…
AUSTIN, Texas, August 27, 2026--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced a new Signatera collaboration with Angiex, Inc., a privately held biotech company develo…